+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Is C-reactive protein an additional, surrogate end-point for statin treatment?

Is C-reactive protein an additional, surrogate end-point for statin treatment?

European Heart Journal 23(10): 761-764

Matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) and ion-pair-reverse-phase high-performance liquid chromatography (IP-RP HPLC) techniques were combined to determine the sequence identity of short single-stranded deoxyoligonucleotides. This methodology is demonstrated using a commercially available multiplex set of eight primer pairs. The primer pairs were separated and collected by IP-RP HPLC.

(PDF emailed within 0-6 h: $19.90)

Accession: 010885946

Download citation: RISBibTeXText

PMID: 12009712

DOI: 10.1053/euhj.2001.3124

Related references

C-reactive protein changes with antihypertensive and statin treatment. Medicina Clinica 125(15): 561-564, 2005

The role of C-reactive protein (CRP) and statin treatment in reducing cardiovascular risk. South Dakota Medicine 62(3): 104-106, 2009

Therapeutic options to further lower C-reactive protein for patients on statin treatment. Current Atherosclerosis Reports 12(1): 34-42, 2010

Associations between change in C-reactive protein and serum lipids during statin treatment. Annals of Medicine 32(8): 579-583, 2000

Statin treatment use in diabetic patients with breast cancer: A potential C-reactive protein mediated benefit. Journal of Clinical Oncology 29(27_suppl): 173-173, 2016

Reduction in High-Sensitivity C-Reactive Protein Levels in Patients with Ischemic Stroke by Statin Treatment: Hs-CRP Sub-Study in J-STARS. Journal of Atherosclerosis and Thrombosis 24(10): 1039-1047, 2017

Association between statin use and lipid status in quality improvement initiatives: statin use, a potential surrogate?. Quality in Primary Care 20(6): 401-407, 2013

Decrease of C-reactive protein serum levels determines the extent improvement in endothelial dysfunction induced by short-term statin treatment. Circulation 106(19 Supplement): II 704, November 5, 2002

Novel surrogate end-point biomarker to evaluate agents for use in the chemoprevention of reactive oxygen species-associated cancer. Redox Report 7(5): 335-338, 2003

Effect of statin treatment in patients with acute myocardial infarction and left ventricular systolic dysfunction according to the level of high-sensitivity C-reactive protein. International Heart Journal 55(2): 106-112, 2014

Point: high-sensitivity C-reactive protein and cardiac C-reactive protein assays: is there a need to differentiate?. Clinical Chemistry 52(7): 1254-1256, 2006

Point-of-Care C-Reactive Protein Testing to Help Guide Treatment of Acute Respiratory Infections. American Family Physician 92(7): 571-572, 2015

Importance of C-reactive protein level in predicting non-response to additional intravenous immunoglobulin treatment in children with Kawasaki disease: a retrospective study. Clinical Drug Investigation 31(3): 191-199, 2011

C-reactive protein: a surrogate marker for atherosclerosis. Current Opinion in Lipidology 15(3): 365-367, 2004

Role of C-reactive protein when prescribing a statin. Current Atherosclerosis Reports 14(1): 26-32, 2012